

Review

Not peer-reviewed version

Investigating the Interplay: Periodontal Disease and Type 1 Diabetes Mellitus - A Comprehensive Review of Clinical Studies

Stefania Vlachou , Alexandre Loume , Catherine Giannopoulou , <u>Evangelos Papathanasiou</u> , <u>Alkisti Zekeridou</u>

Posted Date: 15 April 2024

doi: 10.20944/preprints202404.0917.v1

Keywords: Diabetes mellitus; periodontitis; type 1 diabetes mellitus; molecular mechanisms; cellular mechanisms; oral microbiota; host immune response; oxidative stress; periodontal disease



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Remieri

Investigating the Interplay: Periodontal Disease and Type 1 Diabetes Mellitus—A Comprehensive Review of Clinical Studies

Stefania Vlachou ¹, Alexandre Loume ¹, Catherine Giannopoulou ¹, Evangelos Papathanasiou ² and Alkisti Zekeridou ^{1,*}

- Division of Regenerative Dental Medicine and Periodontology, University Clinics Of Dental Medicine, University of Geneva, Rue Michel-Servet 1, 1211, Geneva 4, Switzerland
- ² Department of Periodontology, Tufts University School of Dental Medicine, One Kneeland street, Boston, MA, 02111, USA
- * Correspondence: alkisti.zekeridou@unige.ch

Abstract: Diabetes mellitus (DM) poses a significant challenge to global health, with its prevalence projected to rise dramatically by 2045. This narrative review explores the bidirectional relationship between periodontitis (PD) and type 1 diabetes mellitus (T1DM), focusing on cellular and molecular mechanisms derived by the interplay between oral microbiota and the host immune response. A comprehensive search of literature published between 2008 and 2023 was conducted to elucidate the association between these two diseases. Preclinical and clinical evidence suggests a bidirectional relationship, with individuals with T1DM exhibiting heightened susceptibility to periodontitis, and vice versa. The review includes recent findings from human clinical studies, revealing variations in oral microbiota composition in T1DM patients, including increases in certain pathogenic species such as Porphyromonas gingivalis, Prevotella intermedia, and Aggregatibacter actinomycetemcomitans, along with shifts in microbial diversity and abundance. Molecular mechanisms underlying this association involve oxidative stress and dysregulated host immune responses, mediated by inflammatory cytokines such as IL-6, IL-8, and MMPs. Furthermore, disruptions in bone turnover markers, such as RANKL and OPG, contribute to periodontal complications in T1DM patients. While preventive measures to manage periodontal complications in T1DM patients may improve overall health outcomes, further research is needed to understand the intricate interactions between oral microbiota, host response, periodontal disease, and systemic health in this population.

Keywords: Diabetes mellitus; periodontitis; type 1 diabetes mellitus; molecular mechanisms; cellular mechanisms; oral microbiota; host immune response; oxidative stress; periodontal disease

Introduction

Diabetes mellitus (DM) is identified as challenge to global health, impacting a substantial segment of the global population. According to projections by the International Diabetes Federation (IDF), the prevalence of diabetes is expected to rise significantly by 2045, 1 in 8 adults, approximately 783 million people are expected to have DM. The two primary types of diabetes mellitus are type 1 (T1DM) and type 2 (T2DM). T1DM also called juvenile-onset or insulin dependent diabetes, characterized by the autoimmune destruction of pancreatic beta-cells resulting in insulin deficiency, predominantly affects young individuals (Atkinson, 2012). T2DM also called adult onset or non-insulin-dependent diabetes, is characterized by insulin resistance.

There is compelling evidence suggesting a bidirectional relationship between periodontitis (PD) and DM, both being chronic inflammatory conditions. Individuals with diabetes demonstrate a higher prevalence of periodontitis, and conversely, those with periodontitis are more prone to diabetes-related complications (Loe, 1993; Taylor, 2001); Ziukaite et al. (2018).

This narrative review aims to elucidate the association between periodontitis and T1DM, focusing on cellular and molecular mechanisms, with particular emphasis on the role of oral microbiota and immune responses. We conducted a comprehensive review of articles pertaining to these two diseases, published in English between 2008 and 2023. Our search utilized the National Library of Medicine, PubMed search engine, employing specific search pathways such as: ((hyperglycemia) AND (diabetes mellitus type I)) AND (modifications in microbiota), type 1 diabetes and periodont* and inflammation, and type 1 diabetes and periodont* and immune response. Few older reference articles frequently cited in the literature were included.

Type 1 Diabetes Mellitus

T1DM is the most common autoimmune disease in young patients. This pathology is characterized by the dysregulation of glucose metabolism, attributed to the gradual autoimmune destruction of pancreatic beta cells. Consequently, individuals with T1DM exhibit insulin deficiency coupled with hyperglycemia (Atkinson, 2012). According to estimates provided by the American Diabetes Association, T1DM accounts for approximately 5-10% of all diabetes cases. Clinical manifestations commonly associated with T1DM include polydipsia, polyphagia, and polyuria (Atkinson, 2012).

The global incidence of T1DM has displayed a consistent upward trend, with rates escalating by 2-5% across various regions worldwide. Significantly considerable heterogeneity in diagnosis exists between different geographic locales or continents (Maahs et al., 2010);(Mobasseri et al., 2020);(Gregory et al., 2022). While the epidemiology of childhood-onset T1DM is extensively documented and routinely updated in the IDF Diabetes Atlas, the landscape of adult-onset T1DM remains less elucidated. This knowledge gap can be attributed to historical biases favoring childhood-onset cases, challenges associated with distinguishing adult-onset T1DM from T2DM, and the absence of comprehensive national diabetes registries encompassing T1DM incidence across all age groups (DiMeglio et al., 2018; Maahs et al., 2010). Nonetheless, it is acknowledged that T1DM predominantly manifests in childhood but can occur at any age.

A recent systematic review conducted by Harding et al. (2022) (Harding et al., 2022) aimed to evaluate the incidence of adult-onset T1DM (occurring in individuals over 20 years of age) across 32 countries and regions. The findings of this review underscored a notable burden of adult-onset T1DM incidence, thereby emphasizing the urgent need to enhance both the quality and quantity of information pertaining to adult-onset T1DM, particularly in low- and middle-income countries.

Clinical Phenotype of T1DM

T1DM presents a multifaceted clinical phenotype predicated on two key assumptions. Firstly, the onset of T1DM is characterized by evidence of islet-directed autoimmunity preceding the manifestation of dysglycemia or hyperglycemia. Secondly, the pathogenesis of T1DM encompasses diverse pathways leading to beta cell destruction, influenced by variables such as age of onset, genetic predisposition, pancreatic pathology, metabolic dysregulation, insulin secretion dynamics, diabetic complications, and therapeutic responses.

The clinical diagnosis of T1DM relies on two primary features: insulin deficiency necessitating exogenous insulin therapy and the presence of islet-directed autoantibodies. These criteria serve as pivotal markers guiding the clinical assessment of the disease.

T1DM progresses through three discernible stages. The initial stage is characterized by the detection of autoantibodies in the absence of hyperglycemia, defining the prediabetic phase. Subsequently, the second stage ensues with the development of hyperglycemia. Finally, overt diabetes manifests in the third stage, marked by the emergence of clinical symptoms revealing the diabetic process (Insel et al., 2015).

Pathogenesis of Type 1 Diabetes Mellitus

Autoantibodies serve as vital biological markers for autoimmune diabetes, albeit their direct involvement in beta-cell destruction is limited. In children under 5 years old who develop diabetes, these autoantibodies are detected in nearly 100% of cases. They often serve as predictive indicators for diabetes occurrence in first-degree relatives of T1DM patients or in newborns from T1DM parents. Their detection typically precedes disease onset by months or even years, varying with the age of onset. Notably, the presence of two or more antibodies before the age of 3 correlates with a 75% risk of developing T1DM within 10 years, while the presence of all four antibodies indicates a 100% risk over a 20-year follow-up period (Pietropaolo et al., 2012).

Contemporary understanding characterizes T1DM as a multifactorial and heterogeneous disease, with diverse trajectories among patients. While the precise mechanisms remain elusive, genetic, and environmental factors are implicated, suggesting an intricate interplay (Alkanani et al., 2015). Among environmental influences, infections, probiotics, micronutrients, and microbiota have emerged as significant factors in either triggering or exacerbating the disease process (Af Segerstad et al., 2022; Houeiss et al., 2022).

Current consensus within the scientific community underscores the autoimmune response to beta cells as precipitated by a myriad of environmental triggers in genetically predisposed individuals. Notably, variations in T1DM incidence among countries likely reflect disparities in susceptibility genetic loci rather than environmental exposures. However, the declining occurrence of high-risk Human leukocyte antigen (HLA) alleles in T1DM cases suggests a pivotal role for gene-environment interactions (Redondo et al., 2018). The initiation of beta-cell autoimmunity involves diverse environmental factors and gene-environment interactions, mediated by the activation of autoreactive CD4+ helper T cells and CD8+ cytotoxic T cells, ultimately leading to beta-cell apoptosis (Powers, 2021; Rodrigues Oliveira et al., 2023).

The subsequent chapter delves into evidence discussing the association between T1DM and periodontitis, incorporating findings from both animal and human studies.

Preclinical and Clinical Evidence

Animal studies have utilized rodent models, including chemically induced and genetically caused T1DM, to investigate the bidirectional relationship between periodontitis and T1DM. Streptozotocin and alloxan can chemically induce an immune-mediated form of T1DM in rodents, while the non-obese diabetic mouse develops an autoimmune affection in the pancreas resembling human T1DM development (Pontes Andersen et al., 2007). Studies have revealed that periodontal bone loss in T1DM rats is three times higher than in normal rats (Kim, Lee, Choi, et al., 2014; Kim, Lee, Gunawardhana, et al., 2014) corroborating findings from human studies on the impact of diabetes on the periodontium. However, few rodent studies have explored the consequences of periodontitis on diabetes.

In human studies the association between the two conditions was explored at the level of prevalence, clinical periodontal parameters, and metabolic control. For instance, a cross-sectional study found that periodontitis affected 15.0% of controls and 57.9% of diabetic patients, with severe periodontitis more prevalent in poorly controlled diabetic patients (Poplawska-Kita et al., 2014). Another study reported that almost one in five T1DM patients also suffer from periodontal disease (Dicembrini et al., 2020). Clinically, diabetic subjects exhibit more plaque, gingival inflammation, and attachment loss compared to controls (Meenawat et al., 2013; Roy et al., 2019b). Additionally, poor glycemic control is associated with worse periodontal clinical parameters (Jindal et al., 2015). These parameters are strongly correlated with diabetes duration and HbA1c levels (Dakovic & Pavlovic, 2008). Moreover, T1DM patients exhibit not only increased susceptibility to periodontal diseases, but also to dental caries particularly when metabolic control is poor (Ferizi et al., 2022; Roy et al., 2019a). Meta-analyses have consistently shown higher prevalence and severity of periodontal disease in diabetic patients, with elevated HbA1c levels linked to worse clinical parameters (Costa et al., 2023; Graves et al., 2020; Reddy & Gopalkrishna, 2022; Ziukaite et al., 2018). Intrestingly, even patients with relatively good metabolic control, such as those treated with continuous subcutaneous insulin

infusion, show a higher prevalence of mild gingivitis compared to non-diabetic individuals (Gregorczyk-Maga et al., 2023).

The effect of periodontal treatment on glycemic control in T1DM patients with periodontitis has equally been studied. While periodontal health improved after treatment, no significant effect on glycemic control was observed (Simpson et al., 2022; Vergnes et al., 2018). Nevertheless, providing periodontal care to diabetic patients remains important.

Type 1 Diabetes Mellitus and Oral Microbiota

Environmental factors have been recognized as significant contributors to the onset and progression of T1DM, with emerging attention on the role of the gut microbiota as evidenced by "The Environmental Determinants of Diabetes in the Young (Group) Study" (Group, 2008). It is hypothesized that the gut microbiome influences T1DM risk through mechanisms such as altered intestinal permeability, modulation of the gut immune system, and molecular mimicry. Animal studies have demonstrated associations between gut flora composition and autoimmune diabetes risk, with *lactobacillus* and *bifidobacterium* linked to diabetes resistance, and *bacteroides* associated with susceptibility (Davis-Richardson & Triplett, 2015).

Similarly, human studies reveal disparities in gut microbiota between diabetic and healthy individuals, with T1DM patients exhibiting less diverse and potentially harmful organisms (Abdellatif & Sarvetnick, 2019). These variations are influenced by factors such as antibiotic use, dietary components, hygiene practices, and geographical location, all which impact microbiome composition.

Clinical investigations on the gut microbiome consistently report increased *Bacteroides species* in T1DM subjects compared to controls, alongside increases in *Bacilli, Enterobacteriaceae, Streptococcus, Ruminococcus,* and *Prevotella,* with decreases noted for *Bifidobacteria, Butyrate-producing bacteria, Haemophilus, Veillonella,* and occasionally *Prevotella.* Recently, Abudqwider et al. (2023) conducted a systematic review exploring the interplay between the gut microbiome, inflammation, and blood glucose parameters in T1DM patients, finding correlations between HbA1c levels and specific microbial abundances, with *Prevotella, Faecalibacterium,* and *Ruminococcaceae* negatively correlated, and *Dorea formicigenerans, Bacteroidetes, Lacrobacillales,* and *Bacteroides* positively correlated. *Bifidobacteria* showed a negative correlation with fasting blood glucose levels (Abuqwider et al., 2023).

These studies collectively indicate that T1DM is associated with gut dysbiosis and increased intestinal permeability, suggesting modulation of the gut microbiome as a novel therapeutic avenue.

Several efforts have been made to identify if similar modifications appear in the oral microbiome based on the hypothesis that various factors, including oral and systemic diseases like diabetes, may contribute to changes in the composition of the oral microbiome (Moskovitz et al., 2021; Pisano et al., 2023). Understanding the microbial variations is particularly complex in T1DM due to the prolonged period between initial β -pancreatic cell damage and clinical disease manifestation (Storling & Pociot, 2017).

Studies on the oral microbial composition in individuals with T1DM (insulin-dependent diabetes mellitus), have revealed variations in the quantity and quality of bacterial species compared to healthy controls. For instance, Mashimo et al. (1983) observed a microflora predominantly composed of *Capnocytophaga species* and *anaerobic vibrios* in individuals with insulin-dependent diabetes mellitus (IDDM) (Mashimo et al., 1983). In contrast, Sastrowijoto et al (1989) reported low levels of *Capnocytophaga species* and elevated levels of *Porphyromonas gingivalis, Prevotella intermedia*, and *Aggregatibacter actinomycetemcomitans* in IDDM patients (Sastrowijoto et al., 1989).

Some studies demonstrated a significant increase in *Gram-negative rods* and *fusiforms* in the subgingival microbial composition of T1DM patients, influenced by age, duration of diabetes, or metabolic control, as indicated by HbA1c scores (Sandholm et al., 1989), while others found a significantly higher percentage of *Prevotella intermedia* in periodontal sites with deep pockets among poorly controlled T1DM patients (Mandell et al., 1992). Examining poorly controlled T1DM patients, they noted elevated levels of pathogens at diseased sites, *including Prevotella intermedia, Prevotella melaninogenica, Campylobacter gracilis, Eikenella corrodens, Fusobacterium nucleatum*, and *Campylobacter*

rectus, with a significantly higher percentage of *Prevotella intermedia* noted at sites with deep pockets and attachment loss. Contrary, another study also compared the periodontal condition and subgingival microbial composition of insulin-dependent juvenile diabetic patients with their non-diabetic siblings, finding no statistically significant differences for the tested microorganisms (Sbordone et al., 1995).

Recent research has further delved into the relationship between glycemic control, oral microbiota composition, and periodontal health in children with T1DM. Sjodin et al. (2012) compared the microbiota of young adults with T1DM since childhood to an age- and sex-matched non-diabetic control group, observing differences in the prevalence of specific bacteria, though not significant (Sjodin et al., 2012). Diabetics with poor metabolic control exhibited a lower frequency of certain bacteria, emphasizing potential distinctions in microbial composition (Sjodin et al., 2012).

Others expanded this investigation by evaluating the subgingival microflora in both insulin-dependent and non-insulin-dependent diabetic patients with periodontitis. Although predominant organisms were identified in the insulin-dependent diabetic group, the study failed to establish statistically significant differences in subgingival microflora between diabetic and healthy individuals (Kumar et al., 2012).

Other studies found no significant difference in the prevalence of putative periodontopathic bacteria between T1DM and healthy children, challenging the notion of an increased risk of periodontitis associated with specific bacterial species in T1DM subjects (Arangannal et al., 2013). Similarly, Lalla et al (2015), suggested similar subgingival infection patterns between individuals with T1DM and healthy controls, particularly under controlled periodontal disease severity conditions (Lalla et al., 2015). Accordingly, Singh-Hüsgen et al. (2016) demonstrated that the oral microflora of diabetic children did not differ significantly from that of healthy subjects, challenging previous notions of altered host responses in diabetics leading to increased tissue destruction (Singh-Husgen et al., 2016).

On the contrary, some investigations on the interplay between diabetes, periodontal parameters, and microbiota, revealed variations in certain microorganisms between periodontitis patients with and without diabetes (Castrillon et al., 2015; Duque et al., 2017; Olczak-Kowalczyk et al., 2015) with specific bacteria, such as the *F. nucleatum* and the *Capnocytophaga spp.* showing strong associations with diabetes (Sakalauskiene et al., 2014).

Recently Mahalakshimi et al (2019) evaluated the risk of periodontitis associated with specific bacteria in T1DM children, revealing differences in gingival health but no statistically significant association with bacterial prevalence (Mahalakshmi et al., 2019). Other studies continued to explore the correlation between HbA1c levels, oral microbiota, and specific bacterial species, uncovering associations with microbial diversity and periodontal disease in T1DM subjects (Jensen et al., 2021);(Chakraborty et al., 2021).

Many characterized the oral microbiota in children and adults with T1DM, identifying distinctions in bacterial abundance, microbial diversity, and specific genera, providing a more comprehensive understanding of the oral microbiome in the context of T1DM (Gregorczyk-Maga et al., 2023; Moskovitz et al., 2021; Pachonski et al., 2021).

In a recent clinical trial, Carelli et al. (2023) explored the association between oral microbiota, dental and periodontal diseases, and glycemic control in T1DM children and adolescents, observing consistent presence of specific bacterial species and associations with poor glycemic control, adverse metabolic outcomes, and oral hygiene practices (Carelli et al., 2023).

The cross-sectional study by Selway et al (2023) further underlined the complexity of the relationship between oral microbiota, periodontal health, and systemic factors in children with T1D, with microbial diversity influenced by periodontal risk markers and familial history of hyperlipidemia. This emphasizes the multifaceted nature of the oral microbiota in this population, suggesting a potential role of *non-Porphyromonas species*, such as *Prevotella*, in contributing to periodontal disease in children with a family history of hyperlipidemia (Selway et al., 2023). This emphasizes the multifaceted nature of the oral microbiota in this population, suggesting a potential role of *non-Porphyromonas species*, such as *Prevotella*, in contributing to periodontal disease in children

with a family history of hyperlipidemia. The disruption of microbial ecosystems in these children may involve putative pathogens that contribute to periodontitis and cardiovascular risk factors in subjects.

The current understanding of bacterial-host interactions in periodontal disease related to T1DM is still limited, emphasizing the necessity for additional research to comprehend the intricate connections between systemic health and periodontitis (Table 1). Furthermore, exploring potential connections between oral microbiota and diabetes during the latent phase offers opportunities for early intervention and potentially delaying disease onset.

Table 1. Clinical studies on microbiological findings in Diabetes Mellitus Type I and periodontal disease.

| | | | disease. | | |
|--------------------------|---|---|---|---|--|
| References | Type of study | Methodology | Types of Samples & Microbiological Analysis | Results | Conclusions |
| Arangann et al., 2013 | Comparative case-control clinical study | | Polymerase chain reaction assay for 6S rRNA gene detection | • No significant statistical difference regarding the prevalence of <i>P. Gingivalis, T. Denticola, and A. actinomycetemcomita ns</i> among T1DM and healthy children • T. Forsythia was less prevalent in diabetic children compared to healthy children | Similar microbiologic findings in T1DM patients and healthy children |
| Carelli et al., 2023 | Cross- sectional study | HbA1c Continuous glucose monitoring metrics (GCM) of glycemic control and glucose variability Saliva sampling | DNA extraction Bacterial culture-based analysis PCR | Actinomyces spp., A. actinomycetemcomita ns, P. intermedia, and Lactobacillus spp. in all subjects S. mutans present in approximately 49.4% of samples Higher presence of S. mutans and Veillonella spp. in subjects with poorer glycemic control (HbA1c, %TIR, %TAR). Association observed even after adjusting for age, sex, and hygiene habits Virtuous habits (toothbrush changes, | Importance of glycemic control and regular oral hygiene in preventing oral microbiota linked to dental and periodontal issues in individuals with T1DM since childhood |

| | | | | professional oral hygiene) negatively correlated with <i>T.</i> forsythia, <i>T.</i> denticola, and <i>P.</i> gingivalis | |
|-------------------------------|---|---|---|--|---|
| Castrillon CA et al., 2015 | exami Comparative • Su case-control plaque s clinical study from th | riodontal nation bgingival samples ne three st sites | DNA extraction by silica | compared to systemically healthy patients without | Subgingival microbiota differences exist between diabetic and non-diabetic patients P.gingivalis and A. actinomycetemcomitans are associated with periodontitis in non-diabetic and diabetic patients, respectively |
| Chakraborty et al., 2021 | Sectional - | ıl plaque pling | Culture based microbial identification and biofilm assay | Higher microbial diversity in diabetes with periodontal disease group S. warneri found only in diabetes with periodontal disease group Higher incidence of S. vitulinus, S. sanguinis, and P. aeruginosa in diabetes with periodontal disease group Strong positive correlation between poor glycemic control and biofilm | T1DM children with worse glycemic control, especially with periodontitis, showed increased biofilm formation and microbial diversity |

- 7

| | | · | <u> </u> | | |
|----------------------------------|---|--|---|--|--|
| | | | | formation in both diabetes with and without periodontal disease | |
| Duque et al., 2016 | Comparative case-control clinical study | from periodontal | • PCR • ELISA | Similar periodontal conditions in T1DM and non-diabetic patients Higher lipid parameters in DM group among patients with gingivitis Increased prevalence of C. sputigena and C. ochracea in periodontal sites of DM children Limited detection of "Red complex" bacteria in both groups Frequent occurrence of F. nucleatum and C. rectus Comparable levels of TNF-α and IL-6 in both | • Gingivitis in type 1 diabetes children associated with <i>C. sputigena</i> and <i>C. ochracea</i> • Overall periodontal health and inflammatory markers similar between the two groups |
| Gregorczyk- Maga et al., 2023 | Pilot study | Samples from the mucosa of the buccal and soft palate, tongue, palatal and buccal dental surfaces, and gingival pockets in adult patients with type 1 diabetes mellitus undergoing treatment with insulin pump therapy | Microbiologival cultures with dilution method or qualitative culture method | • Dominant oral microbiota included Streptococcus and Neisseria • Low incidence of cariogenic S. mutans, Lactobacillus, and periodontal pathogens like Prevotella • Significant differences in CFU counts observed between mucosal and dental surface sites for all strains, Gram-positive, Staphylococci, Streptococci, and Streptococcus oralis strain • Candida species were rare | Adult T1DM patients treated with insulin pomp, distinct differences in oral microbiota were observed in specific niches Identified optimal sampling sites for oral microflora: buccal and palatal mucosa, dental surface, and gingival pockets |

| | | | | Mucosal sites exhibited lower diversity and bacterial counts | |
|------------------------|--|--|---|--|--|
| Jensen et al., 2020 | Cross-sectional study | Dental and periodontal examination Buccal and gingival bacterial sampling | 16S rRNA sequencing | increase in sites with pocket depth >3 mm | Relationship between less favorable glycemic control and increased early markers of periodontal disease Glycemic control is linked to the complexity and richness of plaque microbiota, with diversity increasing as HbA1c levels rise |
| Kumar et al., 2012 | Comparative parallel group clinical study | Sub gingival | Bacterial cultures with 'standard loop semiquantitative method'. | No statistical difference between the three groups (insulin-dependent, non-insulin dependent diabetics and non-diabetic periodontitis patients) | The microbial flora of the periodontitis patients is not influenced by their diabetic status |
| Lalla et al., 2006 | Comparative case-control clinical study | 1 | DNA-DNA hybridizationCytokine multiplex analyses | Elevated levels of <i>E. nodatum</i> in diabetic patients among the i | Controlling for the severity of periodontal disease, both T1DM patients and |

| | | | Checkboard immunoblotting | and after adjustments for microbial load • Diabetic patients exhibited higher serum levels of soluble E- selectin, vascular cell adhesion molecule-1, and adiponectin • Diabetic patients had lower levels of plasminogen activator inhibitor- 1 | non-diabetic controls displayed comparable subgingival infection patterns • Serum antibody responses were similar between diabetic and non-diabetic groups after adjusting for eperiodontal disease severity |
|-----------------------------|---|--|---------------------------|--|--|
| Mahalakshmi et al., 2019 | Comparative case-control clinical study | Periodontal examinationSubgingival plaque sampling | PCR | No statistically significant difference in the prevalence of <i>C. rectus, E. corrodens, P. intermedia, P. nigrescens</i> between type 1 diabetic and healthy children | Negative correlation of T1DM with periodontitis in association to 4 periopathogenic bacteria |
| Mandell et al., 1992 | Cross- sectional study | Periodontal examination Subgingival plaque sampling | Bacterial cultures | Elevated levels of periodontal pathogens at diseased sites, including <i>P. intermedia</i> , <i>P. melaninogenica spp.</i> , and others Higher prevalence of <i>P. intermedia</i> and melaninogenica spp., and Campylobacter rectus at diseased sites Significantly higher percentage of <i>P. intermedia</i> at sites with deep pockets and attachment loss | Correlation observed between periodontal disease in insulin dependent diabetes patients (T1DM) and increased levels of specific pathogens |

| Mashimo et al., 1982 | Cross-sectional study | Periodontal examination Subgingival plaque sampling | Bacterial cultures Immunofluore scence microscopy ELISA | lesions in nondiabetic adults | The subgingival organisms identified in periodontal lesions of individuals with insulin-dependent diabetes (T1DM) exhibit quantitative distinctions from those observed in cases of periodontitis |
|-------------------------|---|--|---|---------------------------------|---|
| 2021 | Comparative case-control clinical study | Periodontal examination | DNA extractionqPCR | • Identified 105 genera and 211 | Salivary microbiome analysis revealed |

| | | • Unstimulated saliva sampling | 16S rRNA library preparation Sequencing | Abondant genera: Streptococcus, Prevotella, Veillonella, Haemophilus, Neisseria Streptococcus more abundant in type 1 diabetes children Catonella, Fusobacterium, Mogibacterium differed between healthy and T1DM subjects Porphyromon as and Mogibacterium correlated with salivary parameters | |
|-------------------------------------|--|--|---|--|--|
| Olczak- Kowalczyk et al. 2015 | Comparative parallel ' group clinical study | General medical examination Periodontal examination Oral bacterial swabs | Bacterial cultures Tests for enzymic profiles | Candida spp. detected in healthy and nephrotic syndrome/T1DM patients Oral candidiasis found in nephrotic syndrome and T1DM patients Gingivitis is more common in nephrotic syndrome/T1DM patients In diabetes, severity linked to blood glucose and glycated haemoglobin >8% | Gingivitis mainly caused by poor hygiene Severity associated with age, lipid disorders, and increased body mass Candida spp. may worsen plaque-related gingivitis in diabetes and immunosuppresse d patients |
| Pachoński et al., 2021 | Comparative case-control clinical study | Oral bacterial swabs | Bacterial cultures Sets of reagents for species identification | Statistically significant differences in the total number of isolated microorganisms were found between poorly controlled T1DM patients and healthy controls | Oral microbiome in T1DM children differs quantitatively and qualitatively from healthy children |

| | | | Statistically significant differences in the total number of isolated microorganisms were found between well controlled T1DM patients and healthy controls No statistically significant differences were observed in the number of isolated microorganisms between poorly and well controlled T1DM patients | |
|-------------------------------|--|---|---|---|
| Sakalauskiene et al., 2014 | Periodontal and radiographic Comparative examination case-control Blood samples clinical study Supra and subgingival plaque sampling | Bacterial cultures Molecular genetic assay | • F. nucleatum, Capnocytophaga species, and E. corrodens were the most frequently identified bacteria in dental plaque samples (• A. actinomycetemcomita ns was 40.7% less frequently identified in the diabetes type 1 group compared to the healthy group • Periodontal disease was more pronounced IN T1DM patients • The prevalence of periodontitis significantly increased in subjects with poorer metabolic control | The presence of two periodontal pathogens, <i>F. nucleatum</i> and <i>Capnocytophaga spp.</i> , showed the strongest relationship with poorer metabolic control in T1DM patients and all clinical parameters of periodontal pathology |
| Sandholm et al., 1989 | Comparative case-control sampling clinical study | Bacterial culturesMicroscopic observation | Rhodes-stained straight and curved | Diabetes patients exhibited lower proportions of cocci and total <i>Gram-positive</i> bacteria but higher proportions of periodontally more |

| | | | compared to controls Controls A Controls have significantly more Gram-positive and Gram-negative cocci, total Gram-positive bacteria, and Rhodes-stained fusiforms than in insulin dependent diabetes patients Controls exhibit higher percentages of spirochetes and flagellated bacteria compared to in insulin dependent diabetes patients The distribution of morphotypes is not influenced by age, duration of diabetes, or metabolic control measured by HbA1c scores in | pathogenic forms, Gram-negative rods, and total Gram- negative bacteria compared to controls even if they had comparable hygiene |
|------------------------------|---|--|--|--|
| Sastrowijoto et al., 1989 | Genemedical Comparative examinati case-control Period clinical study examinati Subgir plaque samj | l Bacterial cultures ion and use of isolation dontal and identification ion media | and duration of diabetes mellitus did not influence | Metabolic control had no direct effect on the periodontium The role of Capnocytophaga species in the pathogenesis of infectious periodontal disease in T1DM patients might be overestimated |
| Sbordone et al., | Comparative case-control clinical study in siblings • Generative medical examination | l cultures and use of | No significant differences detected in any clinical and | Limited distinctions were noted between individuals with |

| | | Periodontal examinationSubgingival plaque sampling | identification media • Biochemical tests | microbiological data | T1DM and their healthy counterparts within this population |
|------------------------------|--|--|---|--|---|
| Selway et al., 2023 | Post-hoc cross- sectional study | Periodontal examination Medical and dental history Gingival swab samples | 16S rRNA gene sequencing | history • Differences were not observed | In children diagnosed with T1DM, findings highlight an association between oral microbiota and two distinct exposure variables: familial history of hyperlipidemia and periodontal risk factors |
| Singh-Hüsgen et al., 2016 | Cross- sectional study | Periodontal and dental examination Medical examination Supra and subgingival plaque sampling | PCR | • A statistically significant difference in the decayed, missing, and filled surfaces (dmfs) index value was observed among the three groups (healthy, type 1 diabetes and phenylketonuria group) • When comparing diabetics to healthy children, a small but statistically significant difference in the Periodontal Index (PBI) score was revealed • Statistically significant differences were found in the counts of Lactobacillus, Leptotrichia, and P. gingivalis among the three groups | Diabetic children displayed a lower caries experience in their primary dentition but were found to have a slightly higher risk of developing periodontal disease |
| Sjdödin et al., 2012 | Comparative case-control clinical study | dental aand | Checkboard DNA- DNA hybridization | including probing | Periodontal and microbiological status in young adults with insulin |

| examination and | marginal bone loss, dependent diabetes |
|---------------------------------|--|
| history | were generally (T1DM) does not |
| Medical | favorable in all differ significantly |
| examination and | patients from that of |
| history | • The healthy controls |
| Subgingival | distribution of |
| plaque sampling | various |
| | microbiological |
| | species was similar |
| | between the study |
| | and control groups |
| | |

T1DM: Type 1 Diabetes Mellitus.

Table 2. Clinical studies on host immune response in Diabetes Mellitus Type I and periodontal disease.

| | - | disease. | - | | - |
|---------------------------|--|---|--|--|---|
| Author | Type of study | Methodology | Types of Samples & Immune Analysis | Results | Conclusions |
| Aral et al., 2017 | Prospective case-control study | 32 T1DM patients at diagnosis, and age- and gendermatched 36 systemically healthy children with (G) and without (H) gingivitis were enrolled for periodontal exam and oxidative stress markers. The diabetic patients who took insulin therapy (1.5 units/kg/day totally) and periodontal treatment (oral hygiene education with professional scaling) were re-evaluated after 3 months. | Total antioxidant status (Pachonski et al.), total oxidant status (TOS), and oxidative stress index (OSI) were measured in saliva, GCF and serum. | GCF, salivary, and serum oxidative stress index (OSI) were higher in group T1DM compared to the other groups at baseline (p < 0.05). GCF, salivary, and serum oxidative stress index (OSI) decreased 3 months after periodontal treatment in T1DM patients. | A substantial level of oxidative stress may occur in children with T1DM, with increased oxidative stress index (OSI) in GCF, salivary, and serum samples. |
| Aroonrangsee et al., 2023 | Cross-sectional case–control study | 40 participants from 15-23 years old. 20 T1DM patients and 20 agematched non-T1DM subjects were enrolled. An average HbA1c level of less than 8% was considered the cut-off between well-controlled and poorly-controlled T1DM. | protein carbonyl, total oxidant status (TOS), and total antioxidant capacity were determined using oxidative and antioxidative assays followed by spectrophotometri | significantly associated with lower total oxidant status (TOS) in saliva (p<0.05). Increased TOS levels were significantly correlated with BOP. No relationship was a found between OS | Salivary total oxidant status (TOS) levels were related to both diabetes status and the extent of gingival inflammation. |

| | | Unstimulated whole saliva was collected before clinical periodontal exam. | at 375–532 nm. | | |
|----------------------|--|--|---|---|--|
| Lappin et al., 2015 | Cross-sectional study | periodontitis, | performance liquid chromatography. Levels of IL-6, IL- | • Higher | Elevated plasma levels of IL-8 potentially contribute to the cross-susceptibility between periodontitis and T1DM. |
| Passoja et al., 2011 | Prospective clinical study | 80 subjects with T1DM (age 38.6 ± 12.3 y.o.) participated in the baseline study visit, while 58 subjects (age 39.5±12.6 y.o.) completed the visit after periodontal therapy. Periodontal therapy included oral hygiene education, scaling and root planning and patients were re-evaluated 8 weeks after periodontal therapy. Periodontal exam and blood samples were drawn at the baseline and in the follow-up visits. | Serum IL-6 levels were measured using ELISA. | • Significant association between the level of serum IL-6 and the number of sites with bleeding and PD≥4mm at the | Subjects with a high IL-6 serum level after therapy presented poorer periodontal healing than those with a low level. IL-6 may have a modulatory effect on host immune response in T1DM patients. |
| Salvi et al., 2010 | Prospective cohort study of experimental gingivitis (EG) | A total of 18 Caucasian subjects (9 patients with T1DM and 9 without diabetes) (age 25.6 ± 5.8 y.o.) were included. EG: Patients were instructed to refrain from all oralhygiene | Periodontal exam and GCF was collected at baseline, Day 7, Day 14, Day 21 and Day 35. IL-1β, IL-8, MMP- 8, and MMP-9 levels were determined by ELISA. | were higher compared to healthy individuals, and showed differences | GCF IL-1β and MMP-9 were most significantly elevated in T1DM subjects compared with healthy individuals during EG, not resulting from differences in the plaque index (PI) |

| | | practices for 21 | | patients showed | or microbial |
|--|--------------------------|---|---|--|--|
| | | days, resuming | | IL-1b increases | composition. |
| | | oral hygiene | | from baseline to | |
| | | practices following | | 14–21 days | |
| | | the 21-day exam, | | (p<0.05). • MMP-9 | |
| | | continuing for an additional 2 weeks | | levels between | |
| | | until Day 35. | | patients with and | |
| | | untin Day 55. | | without T1DM at | |
| | | | | 7–14 | |
| | | | | days (p<0.05). | |
| | | | | • No | |
| | | | | differences in any | CCETT 10 1 |
| | | | | clinical | GCF IL-1β and |
| | | Plasma C-reactive | | periodontal | TNF- α levels were higher in T1DM |
| | | protein and GCF | Plasma high- | parameters | periodontitis |
| | | IL-1β, IL-6 and | sensitive C- | between T1DM | patients compared |
| | | TNF- α were | reactive protein | and T2DM | to T2DM |
| | | measured in | (hs-CRP) | periodontitis | periodontitis ones. |
| | | periodontitis | concentrations | patients. | 1 |
| | | • | were measured by | • GCF IL-1 β and TNF- α were | GCF IL-1β and |
| | | by T1DM (n=24) | a particle- | higher in T1DM | TNF- α levels |
| Aspriello et al., 2011 | | and type 2 | enhanced | periodontitis | higher in cases of |
| Asplicito et al., 2011 | Cross-sectional | | immunoturbidime | patients compared | recent onset of |
| | study | (T2DM) (n=24). | tric | to T2DM | diabetes mellitus |
| | | T1DM nationto | assay. | periodontitis ones. | highlighting the |
| | | T1DM patients had a significantly | GCF mediators | • GCF IL-1β | need for periodontal |
| | | lower age (43.5± | were measured | and TNF- α levels | therapy at the |
| | | 6.5 y.o) compared | with ELISA. | were negatively | early stages of |
| | | to T2DM ones | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | correlated with | T1DM |
| | | (63.5± 15.5 y.o). | | diabetes duration | development. |
| | | , , | | and are higher in cases of recent | • |
| | | | | cases or recent | |
| | | | | | |
| | | | | onset of diabetes | |
| | | | | | |
| | | | | onset of diabetes mellitus. | |
| | | | | onset of diabetes mellitus. • GCF | |
| | | | | onset of diabetes mellitus. GCF concentration of all | |
| | | 20 T1DM patients | | onset of diabetes mellitus. • GCF concentration of all analyzed inflammation markers was lower | |
| | | after simultaneous | | onset of diabetes mellitus. • GCF concentration of all analyzed inflammation markers was lower in the SPK group | |
| | | after simultaneous pancreas and | | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group | Good metabolic |
| | | after simultaneous pancreas and kidney | | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients | Good metabolic control achieved |
| | | after simultaneous pancreas and kidney transplantation | | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) | Good metabolic control achieved by simultaneous |
| | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after | GCF samples were | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients | Good metabolic control achieved by simultaneous pancreas and |
| | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney | collected and IL- | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after | Good metabolic control achieved by simultaneous pancreas and kidney |
| Musial et al., 2021 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation | collected and IL- 1 β , TNF- α , resisting | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower | Good metabolic control achieved by simultaneous pancreas and kidney |
| Musial et al., 2021 | Cross-sectional | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney | collected and IL- 1 β , TNF- α , resistin, YKL-40 were | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower | Good metabolic control achieved by simultaneous pancreas and kidney transplantation |
| Musial et al., 2021 | Cross-sectional study | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non- | collected and IL- 1 β , TNF- α , resistin, YKL-40 were measured with | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease |
| Musial et al., 2021 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non- diabetic kidney | collected and IL- 1β, TNF-α, resistin, YKL-40 were | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in |
| Musial et al., 2021 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. | collected and IL- 1 β , TNF- α , resistin, YKL-40 were measured with | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with end- |
| Musial et al., 2021 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. | collected and IL- 1 β , TNF- α , resistin, YKL-40 were measured with | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of periodontitis | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with endstage renal disease |
| Musial et al., 2021 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. The minimal post-transplant follow- | collected and IL- 1 β , TNF- α , resistin, YKL-40 were measured with | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of periodontitis compared to | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with end- |
| Musial et al., 2021 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. The minimal post-transplant follow-up period was 12 | collected and IL- 1 β , TNF- α , resistin, YKL-40 were measured with | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of periodontitis compared to kidney recipients | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with endstage renal disease |
| Musial et al., 2021 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. The minimal post-transplant follow- | collected and IL- 1 β , TNF- α , resistin, YKL-40 were measured with | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of periodontitis compared to kidney recipients treated with | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with endstage renal disease |
| Musial et al., 2021 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. The minimal post-transplant follow-up period was 12 | collected and IL- 1 β , TNF- α , resistin, YKL-40 were measured with | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of periodontitis compared to kidney recipients treated with insulin but also to | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with endstage renal disease |
| Musial et al., 2021 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. The minimal post-transplant follow-up period was 12 | collected and IL- 1 β , TNF- α , resistin, YKL-40 were measured with | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of periodontitis compared to kidney recipients treated with insulin but also to T1DM patients | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with endstage renal disease |
| Musial et al., 2021 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. The minimal post-transplant follow-up period was 12 | collected and IL- 1 β , TNF- α , resistin, YKL-40 were measured with | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of periodontitis compared to kidney recipients treated with insulin but also to T1DM patients without any | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with endstage renal disease |
| Musial et al., 2021 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. The minimal post-transplant follow-up period was 12 months. | collected and IL- 1 β , TNF- α , resistin, YKL-40 were measured with | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of periodontitis compared to kidney recipients treated with insulin but also to T1DM patients | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with endstage renal disease |
| | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. The minimal post-transplant follow-up period was 12 months. | collected and IL- 1β, TNF-α, resistin, YKL-40 were measured with ELISA. | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of periodontitis compared to kidney recipients treated with insulin but also to T1DM patients without any therapy. | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with endstage renal disease caused by T1DM. |
| Musial et al., 2021 Lappin et al., 2009 | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. The minimal post-transplant follow-up period was 12 months. Plasma concentrations of | collected and IL- 1β, TNF-α, resistin, YKL-40 were measured with ELISA. Plasma levels of RANKL, OPG, C- terminal | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of periodontitis compared to kidney recipients treated with insulin but also to T1DM patients without any therapy. T1DM patients had significantly lower | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with endstage renal disease caused by T1DM. T1DM patients with periodontitis showed lower |
| | | after simultaneous pancreas and kidney transplantation (SPK) and 16 after kidney transplantation (KTx), and 15 non-diabetic kidney recipients (control) were included. The minimal post-transplant follow-up period was 12 months. | collected and IL- 1β, TNF-α, resistin, YKL-40 were measured with ELISA. Plasma levels of RANKL, OPG, C- | onset of diabetes mellitus. GCF concentration of all analyzed inflammation markers was lower in the SPK group than in the group of T1D patients after KTx (P<0.001) Patients with T1DM after SPK showed lower GCF levels of all inflammatory markers and presented reduced intensity of periodontitis compared to kidney recipients treated with insulin but also to T1DM patients without any therapy. T1DM patients had significantly lower | Good metabolic control achieved by simultaneous pancreas and kidney transplantation (SPK) can decrease severity of periodontal inflammation in patients with endstage renal disease caused by T1DM. T1DM patients with periodontitis |

| Cross-sectional of nuclear factor- 1 collagen and concentrations, and higher | OPC |
|---|--------------|
| study kB ligand osteocalcin were lower RANKL to levels than | |
| | |
| | |
| osteoprotegerin ELISA. higher OPG periodon | |
| (OPG), C-terminal concentrations patient | |
| telopeptide of type than suggesting | |
| 1 collagen and non-diabetics. T1DM pat | |
| osteocalcin were • Osteocalcin have a decr | |
| measured in had a negative intrinsic abi | • |
| T1DM patients correlation while replace bone | when |
| (n=63) and non-OPG had a that has b | een |
| diabetics (n=38). positive destroyed of | uring |
| correlation with "acute burs | ts" of |
| The age range of HbA1C. periodon | itis. |
| the subjects was | |
| 22–56 years. | |
| • Patients | |
| with T1DM had | |
| more gingival | |
| inflammation and | |
| a higher | |
| percentage of full | |
| Twenty patients mouth gingival | |
| with T1DM and | lies |
| non-T1DM group, aiming twenty age- | :0 |
| matched non- | the ! |
| salivary samples (PI) was not role of bo | ne |
| T1DM patients for RANK, significantly metabolism | n by |
| Chairatnathrongporn participated (age: RANKL and different. exploring | one |
| et al., 2022 Cross-sectional 18.35 ± 2.01 years). OPG gene • The relative markers | are |
| -t d | |
| study expression was mean mRNA needed in n | itients |
| study expression was mean mRNA needed in p Periodontal exams conducted levels of the with T1DN | |
| study Periodontal exams expression was mean mRNA needed in p and unstimulated conducted. levels of the with T1DA RANK and periodor | I and |
| Periodontal exams and unstimulated whole saliva was expression was mean mRNA needed in p expression was mean mRNA needed in p conducted. levels of the with T1DM RANK and periodor RANKI genes. disease | l and tal |
| Periodontal exams expression was mean mRNA needed in p and unstimulated whole saliva was RANK and periodor | l and tal |
| Periodontal exams and unstimulated whole saliva was collected expression was mean mRNA needed in p expression was mean mRNA needed in p conducted. levels of the with T1DM RANK and periodor RANKL genes, disease | l and tal |
| Periodontal exams and unstimulated whole saliva was collected. expression was mean mRNA needed in p conducted. levels of the with T1DM RANK and periodor RANKL genes, disease collected. and the | I and tal |
| Periodontal exams and unstimulated whole saliva was collected. RANK and periodor RANKL genes, disease collected. RANKL:OPG ratio demonstrated | I and tal |
| Periodontal exams and unstimulated whole saliva was collected. Periodontal exams and unstimulated whole saliva was collected. RANK and periodor RANKL genes, disease and the RANKL:OPG ratio demonstrated higher in the | I and tal |
| Periodontal exams and unstimulated whole saliva was collected. Periodontal exams and unstimulated whole saliva was collected. RANK and periodor RANKL genes, disease and the RANKL:OPG ratio demonstrated | I and tal |

T1DM: Type 1 Diabetes Mellitus; GCF: gingival crevicular fluid; HbA1C: hemoglobin A1C; BOP: bleeding on probing.

Type I Diabetes Mellitus & Host Immune Response

The contribution of a dysregulated exaggerated host immune/inflammatory response in periodontitis is clear. Although a large number of studies describing the bi-directional relationship between periodontitis and T2DM is available in the literature, the potential mechanisms underlying the possible association between T1DM and periodontal diseases remain unclear. While exploring the intricate relationship between T1DM and PD, it becomes evident that the host inflammatory and immune response serve as a key player driving the progression of both diseases. While a significant body of literature has identified the bidirectional association between periodontitis and T2DM, the mechanisms linking T1DM to periodontal diseases remain less understood. However, it is increasingly recognized that periodontal pathologies may represent complications of T1DM, sharing common pathogenic mechanisms with other macro- and micro-vascular complications of diabetes, such as retinopathy and nephropathy (King, 2008).

The host immune response involves inflammation of gingiva and can be modulated by several host-related factors including diabetes mellitus, smoking, genetics and stress (Papathanasiou et al., 2013). The immune response and inflammation emerge as central links between autoimmune disorders like T1DM and PD. Notably, hyperglycemia stands out as a crucial risk factor, triggering

oxidative stress and inflammation that accelerate tissue dysfunction in the periodontium. Several human clinical studies have been undertaken to explore potential immunological pathways connecting these two diseases (Table 2).

Oxidative Stress

Oxidative stress stands as a pivotal factor in the pathogenesis of diabetes mellitus and periodontal diseases, often serving as a reliable marker for screening diabetes-related periodontal dysregulation(Aral et al., 2017). The cascade of hyperglycemia prompts an upsurge in Reactive Oxygen Species (ROS), culminating in structural alterations within proteins, nucleic acids, and lipids, thereby disrupting cellular functionality (Guerra et al., 2011). Notably, heightened levels of oxidative stress markers have been detected in the Gingival Crevicular Fluid (GCF), saliva, and serum of T1DM patients, showing positive correlations with glycated hemoglobin (Aral et al., 2017). Furthermore, oral hygiene education coupled with professional scaling has demonstrated a notable reduction in oxidative stress markers among T1DM patients three months post-periodontal treatment (Aral et al., 2017). However, a recent study among Thai adolescents and young adults with T1DM showed no disparity in salivary oxidative stress biomarkers when compared to their healthy counterparts (Aroonrangsee et al., 2023). Nevertheless, salivary total oxidative status levels were linked to both diabetes status and the extent of gingival inflammation, warranting further exploration through clinical studies encompassing varying degrees of periodontal disease (Aroonrangsee et al., 2023). Additionally, Lipski et al. (2021) revealed that reinforcing proper oral hygiene with antibacterial dentifrices notably reduced specific salivary oxidative stress biomarkers in young T1DM patients with gingivitis (Lipski et al., 2021). Moreover, analyses of GCF microbiology and metabolomics in adults with T1DM undergoing continuous subcutaneous insulin infusion suggested early alterations in the GCF microbiome and metabolite concentrations, potentially attributed to increased oxidative stress markers, thus urging further investigation (Gregorczyk-Maga et al., 2023).

Host Immune Markers

The interplay between high blood glucose levels and sustained chronic inflammatory mediator secretion significantly contributes to an exaggerated periodontal response in individuals with T1DM. Studies investigating the increase in host immune markers in patients with T1DM and periodontal diseases are expected to shed further light into the processes linking T1DM and periodontitis and provide significant value in understanding better the mechanisms behind diabetic complications and introducing novel therapeutic targets. Elevated plasma levels of IL-8 were found in patients with T1DM and periodontitis (Lappin et al., 2015; Linhartova et al., 2018) but also in patients with T1DM independently on their periodontal status (Linhartova et al., 2018) possibly associated with high glucose-induced oxidative stress. Furthermore, serum IL-6 levels have shown positive correlations with the extent of periodontal inflammation in T1DM patients, while serum high-density lipoprotein (HDL) cholesterol levels exhibited negative correlations (Passoja, Knuuttila, Hiltunen, Karttunen, Niemela, et al., 2011; Passoja, Knuuttila, Hiltunen, Karttunen, Niemelä, et al., 2011). Notably, heightened serum IL-6 levels post-periodontal therapy in T1DM patients were linked to poorer periodontal healing responses, suggesting a potential modulation of the host immune response by IL-6 in T1DM patients (Passoja et al., 2011b). Additionally, increased GCF levels of IL-1β and MMP-9 have been reported in T1DM patients during experimental gingivitis, unrelated to microbial differences (Salvi et al., 2010). Conversely, Sereti et al. (2021) found no differences in GCF levels of IL-8, MMP-8, and advanced glycation end products (AGEs) between T1DM and non-diabetic individuals (Sereti et al., 2021). Despite the small sample size, gingival biopsies from adult T1DM patients with aggressive periodontitis exhibited increased expression of MMP-7, -8, -9, and -13 compared to patients without diabetes, underscoring the importance of early periodontal therapy in T1DM (Surlin et al., 2014).

Controversial results have been reported regarding IL-18 levels in children with T1DM due to limitations in collecting samples from an adequate number of patients in order to draw safe conclusions. GCF IL-18 levels were found higher in children with T1DM (n=30) and gingivitis

compared to healthy children with gingivitis (n=13) (Maksymenko et al., 2021), while in a larger study GCF IL-18 levels were similar between diabetic (n=44) and healthy children (n=44) with gingivitis (Keles et al., 2020). While most of the studies compared levels of inflammatory cytokines between diabetic and systemically healthy patients, one very interesting study compared immune markers between T1DM and T2DM with periodontitis (Aspriello et al., 2011). Unexpectedly, GCF IL-1 β and TNF- α levels were higher in T1DM periodontitis patients compared to T2DM periodontitis ones. The authors of this study also showed that GCF IL-1 β and TNF- α levels were negatively correlated with diabetes duration are higher in cases of recent onset of the disease highlighting the need for periodontal therapy at the early stages of T1DM development. Good metabolic control affects periodontal inflammation in diabetic patients. Indeed, T1DM patients post simultaneous pancreas and kidney transplantation displayed lower GCF levels of inflammatory markers and reduced intensity of periodontitis compared to insulin-treated kidney recipients (Musial et al., 2021).

Salivary IgA levels were lower in T1DM patients with diabetic neuropathy compared to healthy individuals, offering a non-invasive method for assessing the risk of developing diabetic neuropathy (Steigmann et al., 2022). Furthermore, a case-control study revealed increased salivary IL-17 levels in diabetic children, highlighting potential immune dysregulation in T1DM (del Valle et al., 2015). Additionally, Yilmaz et al. (2023) demonstrated altered salivary concentrations of macrophage activation-related chemokines and MAPKK-degrading proteolytic activity in T1DM patients showing higher levels of monokine induced by interferon gamma (MIG) and macrophage inflammatory protein-1 alpha (MIP-1 α) in saliva of T1DM patients, underscoring the impact of T1DM on the host immune response (Yilmaz et al., 2023).

Studies exploring bone markers in T1DM patients with periodontitis have revealed intriguing findings. While T1DM patients with periodontitis exhibited lower plasma RANKL:OPG ratios compared to non-diabetic counterparts, they displayed higher serum OPG levels, suggesting impaired bone turnover in T1DM patients during periods of acute periodontitis (Lappin et al., 2009). Similarly, Antonoglou et al. (2013) reported increased serum OPG levels in T1DM patients, positively correlating with the severity of periodontitis, emphasizing the need for further investigation into the role of OPG in T1DM-associated periodontal diseases (Antonoglou et al., 2013). Furthermore, Chairatnathrongporn et al. (2022) observed increased RANKL and RANKL:OPG ratio alongside decreased OPG gene expression levels in saliva of T1DM patients compared to healthy individuals, advocating for more extensive analysis of bone markers in oral fluids to elucidate their role in T1DM and periodontal diseases (Chairatnathrongporn et al., 2022).

While current evidence underscores the intricate interplay between oxidative stress, host immune markers, and periodontal diseases in T1DM patients, further large-scale clinical studies are warranted to validate differences in inflammatory mediators and bone markers between diabetic and non-diabetic individuals across various stages of periodontal diseases.

General Conclusions and Future Suggestions

The dynamic interplay between PD and T1DM highlights the significance of comprehensive dental care in managing diabetes mellitus. It is evident from current research that both diseases share common pathogenic mechanisms. Conducting longitudinal assessments to delineate close interactions between oral microbiota, host response, periodontal disease, and systemic health in T1DM patients could help to develop targeted interventions aimed to mitigate the impact of periodontitis on glycemic control and overall health in individuals with T1DM.

Preventive measures tailored to managing periodontal complications and the use of host modulatory agents in individuals with T1DM can help to improve their overall oral and systemic health outcomes (Balta et al., 2021).

References

- 1. Abdellatif, A. M., & Sarvetnick, N. E. (2019). Current understanding of the role of gut dysbiosis in type 1 diabetes. *J Diabetes*, 11(8), 632-644. https://doi.org/10.1111/1753-0407.12915
- 2. Abuqwider, J., Corrado, A., Scida, G., Lupoli, R., Costabile, G., Mauriello, G., & Bozzetto, L. (2023). Gut microbiome and blood glucose control in type 1 diabetes: a systematic review. *Front Endocrinol (Lausanne)*, 14, 1265696. https://doi.org/10.3389/fendo.2023.1265696
- 3. Af Segerstad, E. M. H., Liu, X., Uusitalo, U., Agardh, D., Aronsson, C. A., & Group, T. S. (2022). Sources of dietary gluten in the first 2 years of life and associations with celiac disease autoimmunity and celiac disease in Swedish genetically predisposed children: The Environmental Determinants of Diabetes in the Young (Group) study. *American Journal of Clinical Nutrition*, 116(2), 394-403. https://doi.org/10.1093/ajcn/nqac086
- 4. Alkanani, A. K., Hara, N., Gottlieb, P. A., Ir, D., Robertson, C. E., Wagner, B. D., Frank, D. N., & Zipris, D. (2015). Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes. *Diabetes*, 64(10), 3510-3520. https://doi.org/10.2337/db14-1847
- 5. Antonoglou, G., Knuuttila, M., Nieminen, P., Vainio, O., Hiltunen, L., Raunio, T., Niemela, O., Hedberg, P., Karttunen, R., & Tervonen, T. (2013). Serum osteoprotegerin and periodontal destruction in subjects with type 1 diabetes mellitus. *J Clin Periodontol*, 40(8), 765-770. https://doi.org/10.1111/jcpe.12129
- 6. Aral, C. A., Nalbantoglu, O., Nur, B. G., Altunsoy, M., & Aral, K. (2017). Metabolic control and periodontal treatment decreases elevated oxidative stress in the early phases of type 1 diabetes onset. *Arch Oral Biol*, 82, 115-120. https://doi.org/10.1016/j.archoralbio.2017.06.009
- 7. Arangannal, P., Santoshkumari, Krishnan, P., Nichani, M. H., Krishnan, M., & Chamarthi, V. (2013). Detection of putative periodontopathic bacteria in type 1 diabetic and healthy children: a comparative study. *Indian J Dent Res*, 24(3), 342-346. https://doi.org/10.4103/0970-9290.118000
- 8. Aroonrangsee, T., Chairatnathrongporn, R., Surarit, R., Tansriratanawong, K., Santiprabhob, J., Boriboonhirunsarn, C., & Promsudthi, A. (2023). Salivary Oxidative Stress Biomarkers in Thai Adolescents and Young Adults with Type 1 Diabetes Mellitus: A Cross-Sectional Study. *J Int Soc Prev Community Dent*, 13(4), 333-341. https://doi.org/10.4103/jispcd.JISPCD_38_23
- 9. Aspriello, S. D., Zizzi, A., Tirabassi, G., Buldreghini, E., Biscotti, T., Faloia, E., Stramazzotti, D., Boscaro, M., & Piemontese, M. (2011). Diabetes mellitus-associated periodontitis: differences between type 1 and type 2 diabetes mellitus. *J Periodontal Res*, 46(2), 164-169. https://doi.org/10.1111/j.1600-0765.2010.01324.x
- 10. Atkinson, M. A. (2012). The pathogenesis and natural history of type 1 diabetes. *Cold Spring Harb Perspect Med*, 2(11). https://doi.org/10.1101/cshperspect.a007641
- 11. Balta, M. G., Papathanasiou, E., Blix, I. J., & Van Dyke, T. E. (2021). Host Modulation and Treatment of Periodontal Disease. *J Dent Res*, 100(8), 798-809. https://doi.org/10.1177/0022034521995157
- 12. Carelli, M., Maguolo, A., Zusi, C., Olivieri, F., Emiliani, F., De Grandi, G., Unali, I., Zerman, N., Signoretto, C., & Maffeis, C. (2023). Oral Microbiota in Children and Adolescents with Type 1 Diabetes Mellitus: Novel Insights into the Pathogenesis of Dental and Periodontal Disease. *Microorganisms*, 11(3). https://doi.org/10.3390/microorganisms11030668
- 13. Castrillon, C. A., Hincapie, J. P., Yepes, F. L., Roldan, N., Moreno, S. M., Contreras, A., & Botero, J. E. (2015). Occurrence of red complex microorganisms and Aggregatibacter actinomycetemcomitans in patients with diabetes. *J Investig Clin Dent*, 6(1), 25-31. https://doi.org/10.1111/jicd.12051
- 14. Chairatnathrongporn, R., Tansriratanawong, K., Santiprabhob, J., Boriboonhirunsarn, C., & Promsudthi, A. (2022). Salivary gene expression of RANK, RANKL, and OPG in type 1 diabetes mellitus and periodontal disease patients. *Journal of International Society of Preventive and Community Dentistry*, 12(6), 603-611. https://doi.org/10.4103/jispcd.JISPCD_184_22
- 15. Chakraborty, P., Chowdhury, R., Bhakta, A., Mukhopahyay, P., & Ghosh, S. (2021). Microbiology of periodontal disease in adolescents with Type 1 diabetes. *Diabetes Metab Syndr*, 15(6), 102333. https://doi.org/10.1016/j.dsx.2021.102333
- 16. Costa, R., Rios-Carrasco, B., Monteiro, L., Lopez-Jarana, P., Carneiro, F., & Relvas, M. (2023). Association between Type 1 Diabetes Mellitus and Periodontal Diseases. *Journal of Clinical Medicine*, 12(3). https://doi.org/10.3390/jcm12031147
- 17. Dakovic, D., & Pavlovic, M. D. (2008). Periodontal disease in children and adolescents with type 1 diabetes in Serbia. *Journal of Periodontology*, 79(6), 987-992. https://doi.org/10.1902/jop.2008.070549
- 18. Davis-Richardson, A. G., & Triplett, E. W. (2015). A model for the role of gut bacteria in the development of autoimmunity for type 1 diabetes. *Diabetologia*, 58(7), 1386-1393. https://doi.org/10.1007/s00125-015-3614-8
- del Valle, L. M. L., Ocasio-López, C., & Steffen, M. (2015). Comparison of Levels of Salivary Cytokines in Diabetic and Nondiabetic Puerto Rican Children: A Case-control Pilot Study. *Pediatric Dentistry*, 37(1), 30-34. <Go to ISI>://WOS:000375729400004
- 20. Dicembrini, I., Serni, L., Monami, M., Caliri, M., Barbato, L., Cairo, F., & Mannucci, E. (2020). Type 1 diabetes and periodontitis: prevalence and periodontal destruction-a systematic review. *Acta Diabetol*, 57(12), 1405-1412. https://doi.org/10.1007/s00592-020-01531-7

- 21. DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018). Type 1 diabetes. *Lancet*, 391(10138), 2449-2462. https://doi.org/Doi 10.1016/S0140-6736(18)31320-5
- 22. Duque, C., Joao, M. F. D., Camargo, G. A. D. G., Teixeira, G. S., Machado, T. S., Azevedo, R. D., Mariano, F. S., Colombo, N. H., Vizoto, N. L., & Mattos-Graner, R. D. (2017). Microbiological, lipid and immunological profiles in children with gingivitis and type 1 diabetes mellitus. *Journal of Applied Oral Science*, 25(2), 217-226. https://doi.org/10.1590/1678-77572016-0196
- 23. Ferizi, L., Bimbashi, V., & Kelmendi, J. (2022). Association between metabolic control and oral health in children with type 1 diabetes mellitus. *Bmc Oral Health*, 22(1). https://doi.org/10.1186/s12903-022-02555-x
- 24. Graves, D. T., Ding, Z. J., & Yang, Y. M. (2020). The impact of diabetes on periodontal diseases. *Periodontology* 2000, 82(1), 214-224. https://doi.org/10.1111/prd.12318
- Gregorczyk-Maga, I., Fiema, M., Kania, M., Jachowicz-Matczak, E., Romaniszyn, D., Gerreth, K., Klupa, T., & Wojkowska-Mach, J. (2023). Oral Microbiota-One Habitat or Diverse Niches? A Pilot Study of Sampling and Identification of Oral Bacterial and Fungal Biota in Patients with Type I Diabetes Mellitus Treated with Insulin Pump. *Int J Environ Res Public Health*, 20(3). https://doi.org/10.3390/ijerph20032252
- 26. Gregory, G. A., Robinson, T. I. G., & Linklater, S. E. (2022). Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study (vol 10, pg 741, 2022). *Lancet Diabetes & Endocrinology*, 10(11), E11-E11. <Go to ISI>://WOS:000884875000011
- 27. Group, T. S. (2008). The Environmental Determinants of Diabetes in the Young (Group) Study. *Ann N Y Acad Sci*, 1150, 1-13. https://doi.org/10.1196/annals.1447.062
- 28. Guerra, J. F. D., Magalhaes, C. L. D., Costa, D. C., Silva, M. E., & Pedrosa, M. L. (2011). Dietary acai modulates ROS production by neutrophils and gene expression of liver antioxidant enzymes in rats. *Journal of Clinical Biochemistry and Nutrition*, 49(3), 188-194. https://doi.org/10.3164/jcbn.11-02
- 29. Harding, J. L., Wander, P. L., Zhang, X. E., Li, X., Karuranga, S., Chen, H. Z., Sun, H., Xie, Y. T., Oram, R. A., Magliano, D. J., Zhou, Z. G., Jenkins, A. J., & Ma, R. C. W. (2022). The Incidence of Adult-Onset Type 1 Diabetes: A Systematic Review From 32 Countries and Regions. *Diabetes Care*, 45(4), 994-1006. https://doi.org/10.2337/dc21-1752
- 30. Houeiss, P., Luce, S., & Boitard, C. (2022). Environmental Triggering of Type 1 Diabetes Autoimmunity. *Frontiers in Endocrinology*, 13. https://doi.org/10.3389/fendo.2022.933965
- 31. Insel, R. A., Dunne, J. L., & Ziegler, A. G. (2015). General population screening for type 1 diabetes: has its time come? *Curr Opin Endocrinol Diabetes Obes*, 22(4), 270-276. https://doi.org/10.1097/med.0000000000000173
- 32. Jensen, E. D., Selway, C. A., Allen, G., Bednarz, J., Weyrich, L. S., Gue, S., Peña, A. S., & Couper, J. (2021). Early markers of periodontal disease and altered oral microbiota are associated with glycemic control in children with type 1 diabetes. *Pediatric Diabetes*, 22(3), 474-481. https://doi.org/10.1111/pedi.13170
- 33. Jindal, A., Parihar, A. S., Sood, M., Singh, P., & Singh, N. (2015). Relationship between Severity of Periodontal Disease and Control of Diabetes (Glycated Hemoglobin) in Patients with Type 1 Diabetes Mellitus. *J Int Oral Health*, 7(Suppl 2), 17-20. https://www.ncbi.nlm.nih.gov/pubmed/26668475
- 34. Keles, S., Anik, A., Cevik, O., Abas, B. I., & Anik, A. (2020). Gingival crevicular fluid levels of interleukin-18 and tumor necrosis factor-alpha in type 1 diabetic children with gingivitis. *Clin Oral Investig*, 24(10), 3623-3631. https://doi.org/10.1007/s00784-020-03238-z
- 35. Kim, J. H., Lee, D. E., Choi, S. H., Cha, J. H., Bak, E. J., & Yoo, Y. J. (2014). Diabetic characteristics and alveolar bone loss in streptozotocin- and streptozotocin-nicotinamide-treated rats with periodontitis. *J Periodontal Res*, 49(6), 792-800. https://doi.org/10.1111/jre.12165
- 36. Kim, J. H., Lee, D. E., Gunawardhana, K. S. N. D., Choi, S. H., Woo, G. H., Cha, J. H., Bak, E. J., & Yoo, Y. J. (2014). Effect of the interaction between periodontitis and type 1 diabetes mellitus on alveolar bone, mandibular condyle and tibia. *Acta Odontologica Scandinavica*, 72(4), 265-273. https://doi.org/10.3109/00016357.2013.822551
- 37. King, G. L. (2008). The Role of Inflammatory Cytokines in Diabetes and Its Complications. *Journal of Periodontology*, 79(8), 1527-1534. https://doi.org/10.1902/jop.2008.080246
- 38. Kumar, V. V., Kumar, K. P., Gafoor, A., & Santhosh, V. C. (2012). Evaluation of subgingival microflora in diabetic and nondiabetic patients. *J Contemp Dent Pract*, 13(2), 157-162. https://doi.org/10.5005/jp-journals-10024-1113
- 39. Lalla, E., Cheng, B., Kunzel, C., Burkett, S., Ferraro, A., & Lamster, I. B. (2015). Six-month outcomes in dental patients identified with hyperglycaemia: a randomized clinical trial. *Journal of Clinical Periodontology*, 42(3), 228-235. https://doi.org/10.1111/jcpe.12358
- 40. Lappin, D. F., Eapen, B., Robertson, D., Young, J., & Hodge, P. J. (2009). Markers of bone destruction and formation and periodontitis in type 1 diabetes mellitus. *Journal of Clinical Periodontology*, 36(8), 634-641. https://doi.org/10.1111/j.1600-051X.2009.01440.x
- 41. Lappin, D. F., Robertson, D., Hodge, P., Treagus, D., Awang, R. A., Ramage, G., & Nile, C. J. (2015). The Influence of Glycated Hemoglobin on the Cross Susceptibility Between Type 1 Diabetes Mellitus and Periodontal Disease. *Journal of Periodontology*, 86(11), 1249-1259. https://doi.org/10.1902/jop.2015.150149

- 42. Linhartova, P. B., Kavrikova, D., Tomandlova, M., Poskerova, H., Rehka, V., Dusek, L., & Holla, L. I. (2018). Differences in Interleukin-8 Plasma Levels between Diabetic Patients and Healthy Individuals Independently on Their Periodontal Status. *International Journal of Molecular Sciences*, 19(10). https://doi.org/10.3390/ijms19103214
- 43. Lipski, J., Duda-Sobczak, A., Napierala, M., Florek, E., Zozulinska-Ziolkiewicz, D., & Wyganowska-Swiatkowska, M. (2021). Influence of Chlorhexidine and Cetylpyridine on Periodontal Status and Indicators of Oxidative Stress in Patients with Type 1 Diabetes. *Antioxidants*, 10(11). https://doi.org/10.3390/antiox10111732
- 44. Loe, H. (1993). Periodontal disease. The sixth complication of diabetes mellitus. *Diabetes Care*, 16(1), 329-334. https://www.ncbi.nlm.nih.gov/pubmed/8422804
- 45. Maahs, D. M., West, N. A., Lawrence, J. M., & Mayer-Davis, E. J. (2010). Epidemiology of Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 39(3), 481++. https://doi.org/10.1016/j.ecl.2010.05.011
- 46. Mahalakshmi, K., Arangannal, P., & Santoshkumari. (2019). Frequency of putative periodontal pathogens among type 1 diabetes mellitus: a case-control study. *Bmc Research Notes*, 12. https://doi.org/10.1186/s13104-019-4364-3
- 47. Maksymenko, A. I., Sheshukova, O. V., Kuz, I. O., Lyakhova, N. A., & Tkachenko, I. M. (2021). The Level of Interleukin-18 in the Oral Fluid in Primary School Children with Chronic Catarrhal Gingivitis and Type I Diabetes Mellitus. *Wiad Lek*, 74(6), 1336-1340. https://www.ncbi.nlm.nih.gov/pubmed/34159915
- 48. Mandell, R. L., Dirienzo, J., Kent, R., Joshipura, K., & Haber, J. (1992). Microbiology of healthy and diseased periodontal sites in poorly controlled insulin dependent diabetics. *Journal of Periodontology*, 63(4), 274-279. https://doi.org/10.1902/jop.1992.63.4.274
- 49. Mashimo, P. A., Yamamoto, Y., Slots, J., Park, B. H., & Genco, R. J. (1983). The periodontal microflora of juvenile diabetics. Culture, immunofluorescence, and serum antibody studies. *Journal of Periodontology*, 54(7), 420-430. https://doi.org/10.1902/jop.1983.54.7.420
- 50. Meenawat, A., Punn, K., Srivastava, V., Meenawat, A. S., Dolas, R. S., & Govila, V. (2013). Periodontal disease and type I diabetes mellitus: Associations with glycemic control and complications. *J Indian Soc Periodontol*, 17(5), 597-600. https://doi.org/10.4103/0972-124X.119286
- 51. Mobasseri, M., Shirmohammadi, M., Amiri, T., Vahed, N., Hosseini Fard, H., & Ghojazadeh, M. (2020). Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. *Health Promot Perspect*, 10(2), 98-115. https://doi.org/10.34172/hpp.2020.18
- 52. Moskovitz, M., Nassar, M., Moriel, N., Cher, A., Faibis, S., Ram, D., Zangen, D., Yassour, M., & Steinberg, D. (2021). Characterization of the Oral Microbiome Among Children With Type 1 Diabetes Compared With Healthy Children. *Front Microbiol*, 12, 756808. https://doi.org/10.3389/fmicb.2021.756808
- 53. Musial, M., Wiench, R., Kolonko, A., Choreza, P., Swietochowska, E., Niedzielski, D., Machorowska-Pieniazek, A., Skaba, D., Wiecek, A., Owczarek, A. J., Niedzielska, I., Król, R., & Ziaja, J. (2021). Type 1 Diabetic Patients After Simultaneous Pancreas and Kidney Transplantation Have Less Intense Periodontal Inflammation Compared to Kidney Recipients Treated with Insulin. *Annals of Transplantation*, 26. https://doi.org/10.12659/AOT.932426
- 54. Olczak-Kowalczyk, D., Pyrzak, B., Dabkowska, M., Panczyk-Tomaszewska, M., Miszkurka, G., Rogozinska, I., Swoboda-Kopec, E., Gozdowski, D., Kalinska, A., Pirog, A., Mizerska-Wasiak, M., & Roszkowska-Blaim, M. (2015). Candida spp. and gingivitis in children with nephrotic syndrome or type 1 diabetes. *Bmc Oral Health*, 15, 57. https://doi.org/10.1186/s12903-015-0042-6
- 55. Pachonski, M., Koczor-Rozmus, A., Mocny-Pachonska, K., Lanowy, P., Mertas, A., & Jarosz-Chobot, P. (2021). Oral microbiota in children with type 1 diabetes mellitus. *Pediatr Endocrinol Diabetes Metab*, 27(2), 100-108. https://doi.org/10.5114/pedm.2021.104343 (Microbiota jamy ustnej u dzieci z cukrzyca typu 1.)
- 56. Papathanasiou, E., Palaska, I., & Theoharides, T. C. (2013). Stress hormones regulate periodontal inflammation. *J Biol Regul Homeost Agents*, 27(3), 621-626. https://www.ncbi.nlm.nih.gov/pubmed/24152831
- 57. Passoja, A., Knuuttila, M., Hiltunen, L., Karttunen, R., Niemela, O., Raunio, T., Vainio, O., Hedberg, P., & Tervonen, T. (2011). Serum high-density lipoprotein cholesterol level associated with the extent of periodontal inflammation in type 1 diabetic subjects. *Journal of Clinical Periodontology*, 38(12), 1071-1077. https://doi.org/10.1111/j.1600-051X.2011.01792.x
- 58. Passoja, A., Knuuttila, M., Hiltunen, L., Karttunen, R., Niemelä, O., Raunio, T., Vainio, O., Hedberg, P., & Tervonen, T. (2011). Serum interleukin-6 may modulate periodontal inflammation in type 1 diabetic subjects. *Journal of Clinical Periodontology*, 38(8), 687-693. https://doi.org/10.1111/j.1600-051X.2011.01731.x
- 59. Pietropaolo, M., Towns, R., & Eisenbarth, G. S. (2012). Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes. *Cold Spring Harb Perspect Med*, 2(10). https://doi.org/10.1101/cshperspect.a012831
- 60. Pisano, M., Giordano, F., Sangiovanni, G., Capuano, N., Acerra, A., & D'Ambrosio, F. (2023). The Interaction between the Oral Microbiome and Systemic Diseases: A Narrative Review. *Microbiology Research*, 14(4), 1862-1878. https://doi.org/10.3390/microbiolres14040127

- 61. Pontes Andersen, C. C., Flyvbjerg, A., Buschard, K., & Holmstrup, P. (2007). Relationship between periodontitis and diabetes: Lessons from rodent studies. *Journal of Periodontology*, 78(7), 1264-1275. https://doi.org/10.1902/jop.2007.060491
- 62. Poplawska-Kita, A., Siewko, K., Szpak, P., Król, B., Telejko, B., Klimiuk, P. A., Stokowska, W., Górska, M., & Szelachowska, M. (2014). Association between type 1 diabetes and periodontal health. *Advances in Medical Sciences*, 59(1), 126-131. https://doi.org/10.1016/j.advms.2014.01.002
- 63. Powers, A. C. (2021). Type 1 diabetes mellitus: much progress, many opportunities. *Journal of Clinical Investigation*, 131(8). https://doi.org/10.1172/JCI142242
- 64. Reddy, M., & Gopalkrishna, P. (2022). Type 1 diabetes and periodontal disease: a literature review. *Can J Dent Hyg*, 56(1), 22-30. https://www.ncbi.nlm.nih.gov/pubmed/35401764
- 65. Redondo, M. J., Steck, A. K., & Pugliese, A. (2018). Genetics of type 1 diabetes. *Pediatric Diabetes*, 19(3), 346-353. https://doi.org/10.1111/pedi.12597
- 66. Rodrigues Oliveira, S. M., Rebocho, A., Ahmadpour, E., Nissapatorn, V., & de Lourdes Pereira, M. (2023). Type 1 Diabetes Mellitus: A Review on Advances and Challenges in Creating Insulin Producing Devices. *Micromachines (Basel)*, 14(1). https://doi.org/10.3390/mi14010151
- 67. Roy, M., Gastaldi, G., Courvoisier, D. S., Mombelli, A., & Giannopoulou, C. (2019a). Periodontal health in a cohort of subjects with type 1 diabetes mellitus. *Clin Exp Dent Res*, 5(3), 243-249. https://doi.org/10.1002/cre2.178
- 68. Roy, M., Gastaldi, G., Courvoisier, D. S., Mombelli, A., & Giannopoulou, C. (2019b). Periodontal health in a cohort of subjects with type 1 diabetes mellitus. *Clinical and Experimental Dental Research*, 5(3), 243-249. https://doi.org/10.1002/cre2.178
- 69. Sakalauskiene, J., Kubilius, R., Gleiznys, A., Vitkauskiene, A., Ivanauskiene, E., & Saferis, V. (2014). Relationship of clinical and microbiological variables in patients with type 1 diabetes mellitus and periodontitis. *Med Sci Monit*, 20, 1871-1877. https://doi.org/10.12659/MSM.890879
- 70. Salvi, G. E., Franco, L. M., Braun, T. M., Lee, A., Persson, G. R., Lang, N. P., & Giannobile, W. V. (2010). Proinflammatory biomarkers during experimental gingivitis in patients with type 1 diabetes mellitus: a proof-of-concept study. *Journal of Clinical Periodontology*, 37(1), 9-16. https://doi.org/10.1111/j.1600-051X.2009.01500.x
- 71. Sandholm, L., Swanljung, O., Rytomaa, I., Kaprio, E. A., & Maenpaa, J. (1989). Morphotypes of the subgingival microflora in diabetic adolescents in Finland. *Journal of Periodontology*, 60(9), 526-528. https://doi.org/10.1902/jop.1989.60.9.526
- 72. Sastrowijoto, S. H., Hillemans, P., van Steenbergen, T. J., Abraham-Inpijn, L., & de Graaff, J. (1989). Periodontal condition and microbiology of healthy and diseased periodontal pockets in type 1 diabetes mellitus patients. *J Clin Periodontol*, 16(5), 316-322. https://doi.org/10.1111/j.1600-051x.1989.tb01662.x
- 73. Sbordone, L., Ramaglia, L., Barone, A., Ciaglia, R. N., Tenore, A., & Iacono, V. J. (1995). Periodontal status and selected cultivable anaerobic microflora of insulin-dependent juvenile diabetics. *Journal of Periodontology*, 66(6), 452-461. https://doi.org/10.1902/jop.1995.66.6.452
- 74. Selway, C. A., Jensen, E. D., Pena, A. S., Smart, G., & Weyrich, L. S. (2023). Type 1 diabetes, periodontal health, and a familial history of hyperlipidaemia is associated with oral microbiota in children: a cross-sectional study. *Bmc Oral Health*, 23(1). https://doi.org/10.1186/s12903-022-02625-0
- 75. Sereti, M., Roy, M., Zekeridou, A., Gastaldi, G., & Giannopoulou, C. (2021). Gingival crevicular fluid biomarkers in type 1 diabetes mellitus: A case-control study. *Clin Exp Dent Res*, 7(2), 170-178. https://doi.org/10.1002/cre2.351
- Simpson, T. C., Clarkson, J. E., Worthington, H. V., MacDonald, L., Weldon, J. C., Needleman, I., Iheozor-Ejiofor, Z., Wild, S. H., Qureshi, A., Walker, A., Patel, V. A., Boyers, D., & Twigg, J. (2022). Treatment of periodontitis for glycaemic control in people with diabetes mellitus. *Cochrane Database Syst Rev*, 4(4), CD004714. https://doi.org/10.1002/14651858.CD004714.pub4
- 77. Singh-Husgen, P., Meissner, T., Bizhang, M., Henrich, B., & Raab, W. H. (2016). Investigation of the oral status and microorganisms in children with phenylketonuria and type 1 diabetes. *Clin Oral Investig*, 20(4), 841-847. https://doi.org/10.1007/s00784-015-1564-7
- 78. Sjodin, B., Edblad, E., Sondell, K., & Dahlen, G. (2012). Minor manifestations of periodontal diseases in young adults with type 1 diabetes mellitus. Periodontal and microbiological findings. *Acta Odontologica Scandinavica*, 70(6), 589-596. https://doi.org/10.3109/00016357.2011.640288
- 79. Steigmann, L., Maekawa, S., Kauffmann, F., Reiss, J., Cornett, A., Sugai, J., Venegas, J., Fan, X., Xie, Y., Giannobile, W. V., Pop-Busui, R., & Lombaert, I. M. A. (2022). Changes in salivary biomarkers associated with periodontitis and diabetic neuropathy in individuals with type 1 diabetes. *Sci Rep*, 12(1), 11284. https://doi.org/10.1038/s41598-022-15430-0
- 80. Storling, J., & Pociot, F. (2017). Type 1 Diabetes Candidate Genes Linked to Pancreatic Islet Cell Inflammation and Beta-Cell Apoptosis. *Genes*, 8(2). https://doi.org/10.3390/genes8020072

- 81. Surlin, P., Oprea, B., Solomon, S. M., Popa, S. G., Mota, M., Mateescu, G. O., Rauten, A. M., Popescu, D. M., Dragomir, L. P., Puiu, I., Bogdan, M., & Popescu, M. R. (2014). Matrix metalloproteinase -7, -8, -9 and -13 in gingival tissue of patients with type 1 diabetes and periodontitis. *Rom J Morphol Embryol*, 55(3 Suppl), 1137-1141. https://www.ncbi.nlm.nih.gov/pubmed/25607396
- 82. Taylor, G. W. (2001). Bidirectional interrelationships between diabetes and periodontal diseases: an epidemiologic perspective. *Ann Periodontol*, *6*(1), 99-112. https://doi.org/10.1902/annals.2001.6.1.99
- 83. Vergnes, J. N., Canceill, T., Vinel, A., Laurencin-Dalicieux, S., Maupas-Schwalm, F., Blasco-Baque, V., Hanaire, H., Arrive, E., Rigalleau, V., Nabet, C., Sixou, M., Gourdy, P., Monsarrat, P., & Group, D. (2018). The effects of periodontal treatment on diabetic patients: The DIAPERIO randomized controlled trial. *J Clin Periodontol*, 45(10), 1150-1163. https://doi.org/10.1111/jcpe.13003
- 84. Yilmaz, N., Polat, R., Gursoy, M., Kaman, W., Gul Aydin, E., Fteita, D., Yilmaz, D., Bikker, F., & Gursoy, U. K. (2023). Salivary macrophage activation-related chemokines and mitogen-activated kinase kinase-degrading proteolytic activity in type 1 diabetes mellitus. *Journal of Periodontology*, 94(7), 896-904. https://doi.org/10.1002/JPER.22-0314
- 85. Ziukaite, L., Slot, D. E., & Van der Weijden, F. A. (2018). Prevalence of diabetes mellitus in people clinically diagnosed with periodontitis: A systematic review and meta-analysis of epidemiologic studies. *J Clin Periodontol*, 45(6), 650-662. https://doi.org/10.1111/jcpe.12839

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.